Acquires and holds Solana tokens for public-market investors, and sells a tongue-stimulation device and therapy for patients with gait or balance problems.
10-K for FY2025, filed Mar 31, 2026
Patients, the U.S. e-commerce partner and Canadian clinics pay for PoNS products, with some U.S. customers paying before shipment; validator arrangements provide SOL staking rewards as the company makes SOL available over time.
10-K for FY2025, filed Mar 31, 2026The staking arrangements represent contracts with customers within the scope of ASC 606, Revenue from Contracts with Customers. Under these…View ↗
In applying ASC 606, the Company evaluates the arrangement by identifying the contract and its term, identifying the performance…View ↗
The Company generates all of its product sales revenue from product sales directly to patients, its e-commerce partner in the United States…View ↗
The Company requires some customers in the United States to prepay the full product selling price, net of cash discount, prior to shipment.…View ↗
10-K for FY2025, filed Mar 31, 2026
FY2025 revenue by product or service (Revenue from Contract with Customer, Excluding Assessed Tax) ↗$6M
10-K for FY2025, filed Mar 31, 2026
$6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
77% |
Product, FY2025
$420K Sources
|
Sold outright |
|
Other revenue
Recurring
10-K for FY2025, filed Mar 31, 2026 |
23% |
Other revenue, FY2025
$128K Sources
|
Recurring |
PoNS products are sold directly to patients and clinics in Canada, and through a U.S. e-commerce partner.
10-K for FY2025, filed Mar 31, 2026The Company generates all of its product sales revenue from product sales directly to patients, its e-commerce partner in the United States…View ↗
No. It lost $40.9M in FY2025.
Growing. Revenue grew 11.5x in 4 years, from $522K in FY2021 to $6M in FY2025, about 84% a year.
A new treasury focus
The business has shifted from a neurotechnology company focused on developing technologies for neurological conditions to a digital-asset treasury focused on acquiring and holding Solana tokens, while retaining neurotechnology operations as a secondary business.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 31, 2026We are a neurotechnology company focused on neurological wellness. Our purpose is to develop, license or acquire non-implantable…View ↗
We are a listed digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”). Solana Company’s DAT objective is…View ↗
We are, to a lesser extent, also a neurotechnology company focused on neurological wellness.View ↗
Following our adoption of our digital asset treasury strategy in September 2025, we continue to operate, to a lesser extent, our…View ↗
Loading...